Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2014 | 06-2014 | 03-2014 | 12-2013 | 09-2013 | |
| Sales | 176,549 | 191,787 | 151,552 | 146,873 | 136,874 |
| Cost of Goods | 29,920 | 31,210 | 22,816 | 17,270 | 28,054 |
| Gross Profit | 146,629 | 160,577 | 128,736 | 129,603 | 108,820 |
| Operating Expenses | 136,346 | 179,669 | 156,008 | 182,183 | 159,598 |
| Operating Income | 11,203 | -18,882 | -26,456 | -52,310 | -50,724 |
| Interest Expense | 9,118 | 9,221 | 9,106 | 7,593 | 526 |
| Other Income | 1,136 | 375 | 938 | 528 | -1,066 |
| Pre-tax Income | 3,221 | -27,728 | -34,624 | -59,375 | -52,316 |
| Income Tax | -4,224 | 5,774 | 3,491 | 2,615 | 704 |
| Net Income Continuous | 7,445 | -33,502 | -38,115 | -61,990 | -53,020 |
| Net Income | $7,445 | $-33,502 | $-38,115 | $-61,990 | $-53,020 |
| EPS Basic Total Ops | 0.05 | -0.23 | -0.26 | -0.44 | -0.38 |
| EPS Basic Continuous Ops | 0.05 | -0.23 | -0.26 | -0.44 | -0.38 |
| EPS Diluted Total Ops | 0.05 | -0.23 | -0.27 | -0.43 | -0.38 |
| EPS Diluted Continuous Ops | 0.05 | -0.23 | -0.26 | -0.44 | -0.38 |
| EBITDA(a) | $27,435 | $-3,365 | $-12,552 | $-52,074 | $-36,092 |